Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant
immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy
(with cisplatin/docetaxel) in primary resectable stage IIIA(N2) NSCLC is efficacious and
feasible.